
PROCF
Healthcare · Drug Manufacturers - Specialty & Generic · $29.2M market cap
$0.01260.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 28, 2024 | Time not confirmed | — | -0.01 | — |
| Dec 26, 2023 | After the close | 0.05 | 0.10 | +100.0% |
| Sep 5, 2023 | Before the open | 0.06 | 0.06 | 0.0% |
| Jun 6, 2023 | Before the open | -0.04 | 0.06 | +250.0% |
| Nov 15, 2022 | Time not confirmed | — | 0.22 | — |
| Aug 30, 2022 | Before the open | 0.10 | 0.03 | -70.0% |
| Jun 15, 2022 | Before the open | 0.01 | 0.16 | +1500.0% |
| Dec 1, 2021 | Time not confirmed | — | -0.33 | — |
Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company develops and manufactures Softgel and related technologies under the Softigel,…